incredible! Qilu's 2 blockbuster varieties have been approved for listing

Today (October 11), the official website of NMPA showed that Qilu Pharmaceutical's ceftazidime avibactam sodium for injection and sunitinib malate capsules were approved for marketing

Ceftazidime Avibactam sodium is a new enzyme inhibitor compound preparation, composed of the third-generation cephalosporin antibacterial drug ceftazidime and the sodium salt of the new β-lactamase inhibitor Avibactam, which can treat drug-resistant gram-negative Bacteria, including infections caused by CRE, multi-drug resistant Pseudomonas aeruginosa, and extended-spectrum-lactamase (ESBLs)-producing bacteria

Sales of Ceftazidime and Avibactam Terminals in Public Medical Institutions in China (Unit: Ten Thousand Yuan)

Source: Mi Nei.

Pfizer's sifotal (ceftazidime and avibactam sodium for injection) was approved for import in China on May 21, 2019

It is worth mentioning that only Qilu Pharmaceutical in China has deployed generic ceftazidime Avibactam sodium for injection and successfully won the first imitation

Sunitinib is a multi-target receptor tyrosine kinase inhibitor developed by Pfizer.

In recent years, the domestic market for sunitinib has continued to expand

Terminal sunitinitant sales in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.

With the approval of Qilu Pharmaceutical's sunitinib malate capsules, there are six domestic manufacturers of the product, including Pfizer, CSPC, Hausen Pharmaceutical, Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical

Data source: Mi Neiwang database, NMPA